About Diaceutics

What do we do?

At Diaceutics we believe that every  patient should get the opportunity to  receive the right test and the right  therapy to positively impact their  disease outcome.  We provide the world’s leading pharma and biotech companies with an  end-to-end commercialisation solution for the launch of precision medicine,  enabled by DXRX - The Diagnostic Network®. We believe that DXRX is  the only diagnostic commercialisation platform designed specifically for  precision medicine, integrating multiple pipelines of real-world, real-time  diagnostic testing data from a global network of labs. Diaceutics’ data  capability is one of the three key value drivers it has integrated into its  unique DXRX platform, alongside its global lab network and product suite tailored for precision medicine.

Over the past two years we have worked consistently with 21 of the global top 30 pharma companies on all  major precision medicine drug launches. Using our bespoke suite of insight and engagement solutions and  advisory services, all underpinned by our unique data and enabled by DXRX - The Diagnostic Network®. These  solutions are helping the world’s largest pharma companies commercialise their precision medicines, enhance  their return on investment and ultimately improve patients lives. 

We are continuing to expand our customer base outside of large pharma and  provide solutions to diagnostic  and biotech companies to enable them to leverage our data insights to support diagnostic commercialisation.

What is precision medicine?

Precision medicine is an innovative approach to tailoring  disease treatment that considers differences in patients’  genetic make-up, environment, and lifestyle. In contrast  to the traditional one-size-fits-all approach, in which  medical treatments are designed for the ‘average’  patient, the goal of precision medicine is to target the right treatments to the right patients at the right time. 

When pharma companies launch a new precision  medicine drug, they require patients to be tested first to  identify if they carry the specific genetic characteristics  (biomarker) to determine if they will respond to that  therapy. These “companion tests” are most often  mandatory and are part of the licence granted by the  FDA or other drug licencing authority. This test-first-then-treat interdependency is what is broadly known  today as precision testing and precision treatment. 

At Diaceutics, we champion ‘better patient testing’ and  recognise its potential to accelerate advancements in  the precision medicine field. Put simply, better testing  alone has the potential to deliver equal or improved  patient outcomes; when better testing leads to better  treatment, the two are transformative. 

As precision medicine evolves over time, patients will  eventually become directly involved in shaping their  own health outcomes. Patient level access to the best  available diagnostic tools and insights will facilitate  a more seamless diagnostic journey and will enable  patients to partner with physicians to make informed  treatment choices. Today, however, we are entering a  ‘middle era’ of precision medicine that sees physicians,  labs, and the industrial ecosystem working to integrate novel testing and treatment choices one or two steps  removed from the patient. Many patients are still not  gaining access to the right tests and, subsequently, the  right treatments. Diaceutics are positioned to work with  pharma and biotech companies to address this

Who are the key players in precision medicine?

Growth in the precision medicine market is evident, with major pharma companies such as AstraZeneca confirming that approximately 90 per cent of their clinical development pipeline is currently driven by precision therapeutics. This growth is being led by technological advances in genetics and improved understanding in molecular diagnostic techniques, enabling better prospects of the successful development of precision therapeutics. Leading pharma companies working in precision medicine include Novartis, Roche/Genentech, AstraZeneca, Pfizer, BMS, Merck and Amgen. Given the specific nature of precision therapeutics, the successful roll-out of these medicines by a pharmaceutical company is increasingly reliant on having effective and widespread testing available for doctors and patients from launch.

Where does Diaceutics fit in this market?

Noting the increasing importance of these market changes, since its inception in 2005, Diaceutics has focused on the diagnostic testing market, collating large amounts of laboratory, patient (on an anonymised and aggregated basis), claims and payor data which it uses to deliver diagnostic testing strategies to its clients. Despite the increasing importance of effective diagnostic testing, the testing market itself is currently highly fragmented and the pharmaceutical industry has varied insight into it.

The Group has amassed a set of data from over 52, 515 laboratories of which show disease volumes and 481 million de-identified patient records globally in 53 countries, insurance claims data for 464,888,990 patients and 453 million testing event data points available weekly. As part of this data collection, it has accumulated a proprietary database of laboratory capabilities across the industry.

What makes us unique?

Diaceutics’ products and services are predominantly focussed on precision testing; being tests carried out in laboratories which are used alongside a precision medicine to identify which patients will benefit most from that drug. The data that Diaceutics has amassed is being harnessed in the development of a unique platform called “DXRX”- the world’s first Diagnostic Network solution for the development and commercialization of precision medicine diagnostics.

How do we add value for our customers?

The Directors believe that DXRX will benefit its pharma clients with improved return on investment, reduced time to peak market penetration and greater revenue potential in relation to their precision therapeutic development programmes. Failure to have effective testing can significantly reduce the adoption of the relevant drug. We strive to improve testing outcomes for patients, enabling better access to the right drug at the right time.